Johnson & Johnson Beats Q1 Estimates, Raises Guidance

Johnson & Johnson reported stronger-than-expected first-quarter results on Tuesday, April 14, 2026, with revenue and adjusted earnings surpassing analyst forecasts, driven by robust sales of its cancer and immunology drugs. The New Jersey-based healthcare company posted quarterly revenue of $24.1 billion, a 10 percent increase from the prior year that topped estimates of $23.6 billion. Adjusted earnings per share reached $2.70, exceeding the consensus projection of $2.66.

The pharmaceutical segment led the performance, generating $15.4 billion in sales, up 11.2 percent year over year and ahead of expectations of $15.2 billion. Key contributors included Darzalex, a multiple myeloma treatment launched in 2015, which recorded $4.0 billion in revenue, surpassing forecasts ranging from $3.4 billion to $3.9 billion. Tremfya, used for psoriasis and inflammatory bowel diseases, brought in $1.6 billion, well above analyst projections of $1.2 billion to $1.4 billion. In contrast, sales of the former blockbuster Stelara plunged 60 percent to $656 million following the loss of patent protection last year, as biosimilar competitors entered the market. At its peak, Stelara exceeded $10...